Good therapeutic response to infliximab in a case of Susac syndrome refractory to immunotherapies including tocilizumab
- 19 January 2022
- journal article
- letter
- Published by Springer Science and Business Media LLC in Zeitschrift für Neurologie
- Vol. 269 (6), 3347-3350
- https://doi.org/10.1007/s00415-021-10922-x
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Recurrence of Susac Syndrome following 23 Years of RemissionCase Reports in Neurology, 2014
- Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter studyJournal of Neuroinflammation, 2014
- Characteristics of Susac syndrome: a review of all reported casesNature Reviews Neurology, 2013
- Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trialArthritis & Rheumatism, 2012
- Cross-regulation of TNF and IFN-α in autoimmune diseasesProceedings of the National Academy of Sciences of the United States of America, 2005
- Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.2004
- Anti–tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritisArthritis & Rheumatism, 2004
- Infliximab as a novel therapy for refractory Kawasaki disease.2004
- Induction of autoantibodies during prolonged treatment with infliximab.2003
- Susac's syndromeNeurology, 1994